Skip to main content

Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.

Publication ,  Journal Article
Philip, PA; Mooney, M; Jaffe, D; Eckhardt, G; Moore, M; Meropol, N; Emens, L; O'Reilly, E; Korc, M; Ellis, L; Benedetti, J; Rothenberg, M ...
Published in: J Clin Oncol
November 20, 2009

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer mortality, despite significant improvements in diagnostic imaging and operative mortality rates. The 5-year survival rate remains less than 5% because of microscopic or gross metastatic disease at time of diagnosis. The Clinical Trials Planning Meeting in pancreatic cancer was convened by the National Cancer Institute's Gastrointestinal Cancer Steering Committee to discuss the integration of basic and clinical knowledge in the design of clinical trials in PDAC. Major emphasis was placed on the enhancement of research to identify and validate the relevant targets and molecular pathways in PDAC, cancer stem cells, and the microenvironment. Emphasis was also placed on developing rational combinations of targeted agents and the development of predictive biomarkers to assist selection of patient subsets. The development of preclinical tumor models that are better predictive of human PDAC must be supported with wider availability to the research community. Phase III clinical trials should be implemented only if there is a meaningful clinical signal of efficacy and safety in the phase II setting. The emphasis must therefore be on performing well-designed phase II studies with uniform sets of basic entry and evaluation criteria with survival as a primary endpoint. Patients with either metastatic or locally advanced PDAC must be studied separately.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

November 20, 2009

Volume

27

Issue

33

Start / End Page

5660 / 5669

Location

United States

Related Subject Headings

  • United States
  • Survival Analysis
  • Risk Assessment
  • Prognosis
  • Practice Guidelines as Topic
  • Pancreatic Neoplasms
  • Pancreatectomy
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Neoplasm Invasiveness
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Philip, P. A., Mooney, M., Jaffe, D., Eckhardt, G., Moore, M., Meropol, N., … Tepper, J. (2009). Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol, 27(33), 5660–5669. https://doi.org/10.1200/JCO.2009.21.9022
Philip, Philip A., Margaret Mooney, Deborah Jaffe, Gail Eckhardt, Malcolm Moore, Neal Meropol, Leisha Emens, et al. “Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.J Clin Oncol 27, no. 33 (November 20, 2009): 5660–69. https://doi.org/10.1200/JCO.2009.21.9022.
Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, et al. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol. 2009 Nov 20;27(33):5660–9.
Philip, Philip A., et al. “Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.J Clin Oncol, vol. 27, no. 33, Nov. 2009, pp. 5660–69. Pubmed, doi:10.1200/JCO.2009.21.9022.
Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, Emens L, O’Reilly E, Korc M, Ellis L, Benedetti J, Rothenberg M, Willett C, Tempero M, Lowy A, Abbruzzese J, Simeone D, Hingorani S, Berlin J, Tepper J. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol. 2009 Nov 20;27(33):5660–5669.

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

November 20, 2009

Volume

27

Issue

33

Start / End Page

5660 / 5669

Location

United States

Related Subject Headings

  • United States
  • Survival Analysis
  • Risk Assessment
  • Prognosis
  • Practice Guidelines as Topic
  • Pancreatic Neoplasms
  • Pancreatectomy
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Neoplasm Invasiveness